Child Psychiatry & Human Development

, Volume 45, Issue 2, pp 185–192

A Head-to-Head Comparison of Aripiprazole and Risperidone for Safety and Treating Autistic Disorders, a Randomized Double Blind Clinical Trial

  • Ahmad Ghanizadeh
  • Aliakbar Sahraeizadeh
  • Michael Berk
Original Article

DOI: 10.1007/s10578-013-0390-x

Cite this article as:
Ghanizadeh, A., Sahraeizadeh, A. & Berk, M. Child Psychiatry Hum Dev (2014) 45: 185. doi:10.1007/s10578-013-0390-x

Abstract

Aripiprazole and risperidone are the only FDA approved medications for treating irritability in autistic disorder, however there are no head-to-head data comparing these agents. This is the first prospective randomized clinical trial comparing the safety and efficacy of these two medications in patients with autism spectrum disorders. Fifty nine children and adolescents with autism spectrum disorders were randomized to receive either aripiprazole or risperidone for 2 months. The primary outcome measure was change in Aberrant Behavior Checklist (ABC) scores. Adverse events were assessed. Aripiprazole as well as risperidone lowered ABC scores during 2 months. The rates of adverse effects were not significantly different between the two groups. The safety and efficacy of aripiprazole (mean dose 5.5 mg/day) and risperidone (mean dose 1.12 mg/day) were comparable. The choice between these two medications should be on the basis of clinical equipoise considering the patient’s preference and clinical profile.

Keywords

AutismTreatmentAripiprazoleRisperidoneClinical trialRandomized

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Ahmad Ghanizadeh
    • 1
    • 2
  • Aliakbar Sahraeizadeh
    • 1
    • 2
  • Michael Berk
    • 3
    • 4
  1. 1.School of Medicine, Research Center for Psychiatry and Behavioral SciencesShiraz University of Medical Sciences, School of MedicineShirazIran
  2. 2.Department of Psychiatry, School of MedicineShiraz University of Medical Sciences, School of MedicineShirazIran
  3. 3.School of MedicineDeakin UniversityGeelongAustralia
  4. 4.Department of Psychiatry, Orygen Research Centre, The Florey Institute of Neuroscience and Mental HealthUniversity of MelbourneMelbourneAustralia